These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B. Zhang N; Zhang X; Zhu J; Turpoff A; Chen G; Morrill C; Huang S; Lennox W; Kakarla R; Liu R; Li C; Ren H; Almstead N; Venkatraman S; Njoroge FG; Gu Z; Clausen V; Graci J; Jung SP; Zheng Y; Colacino JM; Lahser F; Sheedy J; Mollin A; Weetall M; Nomeir A; Karp GM J Med Chem; 2014 Mar; 57(5):2121-35. PubMed ID: 24266880 [TBL] [Abstract][Full Text] [Related]
4. Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B. Zhang N; Turpoff A; Zhang X; Huang S; Liu Y; Almstead N; Njoroge FG; Gu Z; Graci J; Jung SP; Pichardo J; Colacino J; Lahser F; Ingravallo P; Weetall M; Nomeir A; Karp GM Bioorg Med Chem Lett; 2016 Jan; 26(2):594-601. PubMed ID: 26652483 [TBL] [Abstract][Full Text] [Related]
5. Discovery and Structure-Resistance Relationship Study of New Thieno[2,3- Xiao KJ; Zuo WQ; Xu Y; Tao X; Yu LT; Wang NY Pharmazie; 2019 Jun; 74(6):321-325. PubMed ID: 31138367 [TBL] [Abstract][Full Text] [Related]
6. Discovery and structure-activity relationships study of novel thieno[2,3-b]pyridine analogues as hepatitis C virus inhibitors. Wang NY; Zuo WQ; Xu Y; Gao C; Zeng XX; Zhang LD; You XY; Peng CT; Shen Y; Yang SY; Wei YQ; Yu LT Bioorg Med Chem Lett; 2014 Mar; 24(6):1581-8. PubMed ID: 24529869 [TBL] [Abstract][Full Text] [Related]
8. Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B. Dufner-Beattie J; O'Guin A; O'Guin S; Briley A; Wang B; Balsarotti J; Roth R; Starkey G; Slomczynska U; Noueiry A; Olivo PD; Rice CM Antimicrob Agents Chemother; 2014 Jun; 58(6):3399-410. PubMed ID: 24709254 [TBL] [Abstract][Full Text] [Related]
9. Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease. Sheng XC; Appleby T; Butler T; Cai R; Chen X; Cho A; Clarke MO; Cottell J; Delaney WE; Doerffler E; Link J; Ji M; Pakdaman R; Pyun HJ; Wu Q; Xu J; Kim CU Bioorg Med Chem Lett; 2012 Apr; 22(7):2629-34. PubMed ID: 22366653 [TBL] [Abstract][Full Text] [Related]
10. Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C Virus NS4B protein. Gu Z; Graci JD; Lahser FC; Breslin JJ; Jung SP; Crona JH; McMonagle P; Xia E; Liu S; Karp G; Zhu J; Huang S; Nomeir A; Weetall M; Almstead NG; Peltz SW; Tong X; Ralston R; Colacino JM Antimicrob Agents Chemother; 2013 Jul; 57(7):3250-61. PubMed ID: 23629699 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and structure-activity relationships of novel imidazo[4,5-c]pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B. Liu M; Xu Q; Guo S; Zuo R; Hong Y; Luo Y; Li Y; Gong P; Liu Y Bioorg Med Chem; 2018 May; 26(9):2621-2631. PubMed ID: 29681484 [TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein. Tai VW; Garrido D; Price DJ; Maynard A; Pouliot JJ; Xiong Z; Seal JW; Creech KL; Kryn LH; Baughman TM; Peat AJ Bioorg Med Chem Lett; 2014 May; 24(10):2288-94. PubMed ID: 24731273 [TBL] [Abstract][Full Text] [Related]
13. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. Jiang Y; Andrews SW; Condroski KR; Buckman B; Serebryany V; Wenglowsky S; Kennedy AL; Madduru MR; Wang B; Lyon M; Doherty GA; Woodard BT; Lemieux C; Geck Do M; Zhang H; Ballard J; Vigers G; Brandhuber BJ; Stengel P; Josey JA; Beigelman L; Blatt L; Seiwert SD J Med Chem; 2014 Mar; 57(5):1753-69. PubMed ID: 23672640 [TBL] [Abstract][Full Text] [Related]
14. PTC725, an NS4B-Targeting Compound, Inhibits a Hepatitis C Virus Genotype 3 Replicon, as Predicted by Genome Sequence Analysis and Determined Experimentally. Graci JD; Jung SP; Pichardo J; Lahser F; Tong X; Gu Z; Colacino JM Antimicrob Agents Chemother; 2016 Dec; 60(12):7060-7066. PubMed ID: 27620477 [TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Raboisson P; de Kock H; Rosenquist A; Nilsson M; Salvador-Oden L; Lin TI; Roue N; Ivanov V; Wähling H; Wickström K; Hamelink E; Edlund M; Vrang L; Vendeville S; Van de Vreken W; McGowan D; Tahri A; Hu L; Boutton C; Lenz O; Delouvroy F; Pille G; Surleraux D; Wigerinck P; Samuelsson B; Simmen K Bioorg Med Chem Lett; 2008 Sep; 18(17):4853-8. PubMed ID: 18678486 [TBL] [Abstract][Full Text] [Related]
16. Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies. Venkatraman S; Blackman M; Wu W; Nair L; Arasappan A; Padilla A; Bogen S; Bennett F; Chen K; Pichardo J; Tong X; Prongay A; Cheng KC; Girijavallabhan V; George Njoroge F Bioorg Med Chem; 2009 Jul; 17(13):4486-95. PubMed ID: 19481946 [TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymerase. Chen KX; Vibulbhan B; Yang W; Sannigrahi M; Velazquez F; Chan TY; Venkatraman S; Anilkumar GN; Zeng Q; Bennet F; Jiang Y; Lesburg CA; Duca J; Pinto P; Gavalas S; Huang Y; Wu W; Selyutin O; Agrawal S; Feld B; Huang HC; Li C; Cheng KC; Shih NY; Kozlowski JA; Rosenblum SB; Njoroge FG J Med Chem; 2012 Jan; 55(2):754-65. PubMed ID: 22148957 [TBL] [Abstract][Full Text] [Related]
18. Discovery of imidazo[2,1-b]thiazole HCV NS4B inhibitors exhibiting synergistic effect with other direct-acting antiviral agents. Wang NY; Xu Y; Zuo WQ; Xiao KJ; Liu L; Zeng XX; You XY; Zhang LD; Gao C; Liu ZH; Ye TH; Xia Y; Xiong Y; Song XJ; Lei Q; Peng CT; Tang H; Yang SY; Wei YQ; Yu LT J Med Chem; 2015 Mar; 58(6):2764-78. PubMed ID: 25710739 [TBL] [Abstract][Full Text] [Related]
19. Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates. Rajyaguru S; Yang H; Martin R; Miller MD; Mo H Antiviral Res; 2013 Nov; 100(2):328-36. PubMed ID: 24013002 [TBL] [Abstract][Full Text] [Related]
20. Hepatitis C replication inhibitors that target the viral NS4B protein. Miller JF; Chong PY; Shotwell JB; Catalano JG; Tai VW; Fang J; Banka AL; Roberts CD; Youngman M; Zhang H; Xiong Z; Mathis A; Pouliot JJ; Hamatake RK; Price DJ; Seal JW; Stroup LL; Creech KL; Carballo LH; Todd D; Spaltenstein A; Furst S; Hong Z; Peat AJ J Med Chem; 2014 Mar; 57(5):2107-20. PubMed ID: 23544424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]